Merck & Co. Pays Daiichi Sankyo US$4 B Upfront for Cancer ADCs

By Ayush Saxena

Pharma Deals Review: Vol 2023 Issue 11 (Table of Contents)

Published: 1 Nov-2023

DOI: 10.3833/pdr.v2023.i11.2832     ISSN: 1756-7874

Section: Research & Development



In a bid to bolster its oncology portfolio, Merck & Co...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details